4/17
10:27 am
mgtx
Evercore Maintains Positive Stance on MeiraGTx Holdings plc (MGTX) Amid Sector Revisions [Yahoo! Finance]
Low
Report
Evercore Maintains Positive Stance on MeiraGTx Holdings plc (MGTX) Amid Sector Revisions [Yahoo! Finance]
4/17
10:18 am
mgtx
MeiraGTx (MGTX) had its price target raised by Royal Bank Of Canada from $16.00 to $24.00. They now have an "outperform" rating on the stock.
Low
Report
MeiraGTx (MGTX) had its price target raised by Royal Bank Of Canada from $16.00 to $24.00. They now have an "outperform" rating on the stock.
4/16
07:47 am
mgtx
MeiraGTx Announces Pricing of $100 Million Offering of Ordinary Shares
Low
Report
MeiraGTx Announces Pricing of $100 Million Offering of Ordinary Shares
4/16
07:00 am
mgtx
MeiraGTx Announces Positive Three-year Data from the Phase 1 AQUAx Clinical Study of AAV-hAQP1 for the Treatment of Grade 2/3 Late Radiation-Induced Xerostomia
High
Report
MeiraGTx Announces Positive Three-year Data from the Phase 1 AQUAx Clinical Study of AAV-hAQP1 for the Treatment of Grade 2/3 Late Radiation-Induced Xerostomia
4/14
08:30 am
mgtx
MeiraGTx to Present 3-Year Data from the Phase 1 AQUAx Clinical Study of AAV-hAQP1 for the Treatment of Grade 2/3 Radiation-Induced Xerostomia on Thursday, April 16, 2026
High
Report
MeiraGTx to Present 3-Year Data from the Phase 1 AQUAx Clinical Study of AAV-hAQP1 for the Treatment of Grade 2/3 Radiation-Induced Xerostomia on Thursday, April 16, 2026
4/5
01:06 am
mgtx
Medium
Report
3/30
03:25 pm
mgtx
MeiraGTx Holdings plc (NASDAQ:MGTX) Just Reported And Analysts Have Been Cutting Their Estimates [Yahoo! Finance]
Medium
Report
MeiraGTx Holdings plc (NASDAQ:MGTX) Just Reported And Analysts Have Been Cutting Their Estimates [Yahoo! Finance]
3/27
04:46 pm
mgtx
MeiraGTx Holdings plc (MGTX) Presents at RBC Capital Markets Virtual Ophthalmology Conference Transcript [Seeking Alpha]
Low
Report
MeiraGTx Holdings plc (MGTX) Presents at RBC Capital Markets Virtual Ophthalmology Conference Transcript [Seeking Alpha]
3/27
01:57 pm
mgtx
MeiraGTx (MGTX) had its price target lowered by Piper Sandler from $30.00 to $26.00. They now have an "overweight" rating on the stock.
Low
Report
MeiraGTx (MGTX) had its price target lowered by Piper Sandler from $30.00 to $26.00. They now have an "overweight" rating on the stock.
3/27
10:22 am
mgtx
MeiraGTx (MGTX) had its price target raised by Bank of America Corporation from $14.00 to $16.00. They now have a "buy" rating on the stock.
Low
Report
MeiraGTx (MGTX) had its price target raised by Bank of America Corporation from $14.00 to $16.00. They now have a "buy" rating on the stock.
3/27
08:02 am
mgtx
MeiraGTx (MGTX) had its "buy" rating reaffirmed by Chardan Capital. They now have a $35.00 price target on the stock.
Low
Report
MeiraGTx (MGTX) had its "buy" rating reaffirmed by Chardan Capital. They now have a $35.00 price target on the stock.
3/26
08:00 am
mgtx
MeiraGTx Announces FDA Breakthrough Therapy Designation for AAV2-hAQP1 for the Treatment of Grade 2 and Grade 3 Radiation-Induced Xerostomia (RIX) and Reports Fourth Quarter and Full Year 2025 Financial and Operational Results
High
Report
MeiraGTx Announces FDA Breakthrough Therapy Designation for AAV2-hAQP1 for the Treatment of Grade 2 and Grade 3 Radiation-Induced Xerostomia (RIX) and Reports Fourth Quarter and Full Year 2025 Financial and Operational Results
3/11
07:18 am
mgtx
MeiraGTx (MGTX) was upgraded by Zacks Research from "strong sell" to "hold".
Low
Report
MeiraGTx (MGTX) was upgraded by Zacks Research from "strong sell" to "hold".
2/3
08:00 am
mgtx
ZipBio and MeiraGTx Enter into Exclusive License Agreement to Advance First-in-Class AAV Gene Therapy for Geographic Atrophy
Low
Report
ZipBio and MeiraGTx Enter into Exclusive License Agreement to Advance First-in-Class AAV Gene Therapy for Geographic Atrophy
2/3
07:12 am
mgtx
MeiraGTx (NASDAQ:MGTX) was downgraded by analysts at Zacks Research from a "hold" rating to a "strong sell" rating.
Low
Report
MeiraGTx (NASDAQ:MGTX) was downgraded by analysts at Zacks Research from a "hold" rating to a "strong sell" rating.
1/28
01:07 pm
mgtx
Eli Lilly outlays $1.12bn for hearing loss gene therapy partnership [Yahoo! Finance]
Low
Report
Eli Lilly outlays $1.12bn for hearing loss gene therapy partnership [Yahoo! Finance]